ema retatrutide approval shows promise for weight loss and is rumored to be stronger than Ozempic or Mounjaro but is not yet approved by regulatory bodies like the FDA, meaning its long-term safety and full risk Phase 2 Trial of Retatrutide

GLP-1 medicationsshort for glucagon-like peptide-1 receptor agonistsare prescription drugs that help regulate appetite, slow digestion, and improve blood sugar control

Another meta-analysis, which looked at relevant data from multiple clinical studies, estimated that 40-70% of people on GLP-1 drugs will experience nausea at some point while taking the medication

Crucially, glucagon receptor activation increases energy expenditure and promotes preferential utilization of fat stores, creating a metabolic environment optimized for fat oxidation rather than muscle catabolism

Oral formulations of both compounds typically clear faster than injectable versions because they bypass the subcutaneous depot effect that extends release

Issued in Singapore by William Blair International (Singapore) Pte

Intensity Preservation While volume decreases, intensity should remain high